Clinical and Molecular Characterization of Axial Psoriatic Arthritis (PsA), A Pilot Study

Open to people ages 18-80

• Persons with PsA diagnosed by a consultant Rheumatologist with disease duration of > 3 months but < 10 years with or without IBP.
  • Adults between the ages 18 and 80 years, with joint disease onset after 16 years of age
  • Patients able to understand and complete consent procedures

  • Study participants must have PsA, meet CASPAR criteria, and must have active disease as defined by the treating rheumatologist, including an evaluable psoriatic skin lesion amenable to 6mm punch skin biopsy.

    o Psoriasis should be diagnosed by a consultant rheumatologist or dermatologist.

  • Study participants must have been on consistent therapy for their PsA for the past 90 days

  • Study participants must be naïve to biological treatment and targeted synthetic

    DMARD treatment (examples: JAK inhibitors, apremilast)

• • Persons with musculoskeletal (peripheral or axial) symptoms for >10 years
  • Persons with planned major surgery (e.g., joint replacement) within the duration of the collection of data for the study
  • Persons with a history of chemotherapy, radiation therapy or immunotherapy for cancer in the preceding 5 years.
  • Persons with ongoing cancer (not excluding non-melanoma skin, cervical/breast in-situ carcinoma) but those fully recovered from an episode of cancer (in remission for more than 5 years) may be included at the discretion of the patient's treating rheumatologist.
  • Persons with an active severe or serious infection
  • Patients with non-severe infection at the discretion of the Investigator
  • Persons with other concomitant disorders incompatible with study (at discretion of Investigator).